The company's financial position shows an accumulated deficit of $448.0 million as of 2026Q1, which significantly pressures the equity base and highlights the substantial capital requirements for late-stage development.
| Total Current Assets | 348.7M | 332.9M | 226.98M | 159.97M | 182.62M | 42.95M |
| Cash & Short-Term Investments | 326.38M | 312.82M | 218.86M | 150.39M | 163.37M | 37.28M |
| Cash Only | 62.1M | 45.54M | 74.29M | 150.39M | 163.37M | 37.28M |
| Short-Term Investments | 264.28M | 267.28M | 144.57M | 0 | 0 | 0 |
| Accounts Receivable | 0 | 0 | 500K | 0 | 0 | 0 |
| Days Sales Outstanding | - | - | - | - | - | - |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - |
| Other Current Assets | 22.32M | 20.08M | 0 | 9.21M | 18.92M | 5.64M |
| Total Non-Current Assets | 595K | 272K | 47.96M | 3.13M | 211K | 87K |
| Property, Plant & Equipment | 370K | 13K | 154K | 291K | 139K | 0 |
| Fixed Asset Turnover | 0.00x | - | - | - | - | - |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 23.9M | 0 | 47.68M | 0 | 0 | 0 |
| Other Non-Current Assets | 225K | 259K | 126K | 2.84M | 72K | 87K |
| Total Assets | 349.3M | 333.17M | 274.94M | 163.1M | 182.83M | 43.04M |
| Asset Turnover | 0.00x | - | - | - | - | - |
| Asset Growth % | 82.09% | 21.18% | 68.57% | -10.79% | 324.81% | - |
| Total Current Liabilities | 25M | 25.95M | 17.27M | 11.62M | 8.36M | 1.82M |
| Accounts Payable | 8.73M | 5.93M | 3.78M | 4.53M | 3.09M | 293K |
| Days Payables Outstanding | - | - | - | - | - | - |
| Short-Term Debt | 99K | 14K | 0 | 0 | 0 | 0 |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 16.17M | 20M | 4.16M | 0 | 0 | 0 |
| Current Ratio | 13.95x | 12.83x | 13.14x | 13.76x | 21.84x | 23.63x |
| Quick Ratio | 13.95x | 12.83x | 13.14x | 13.76x | 21.84x | 23.63x |
| Cash Conversion Cycle | - | - | - | - | - | - |
| Total Non-Current Liabilities | 320K | 0 | 14K | 177K | 11K | 0 |
| Long-Term Debt | 320K | 0 | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 0 | 0 | 14K | 177K | 11K | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | 25.32M | 25.95M | 17.29M | 11.8M | 8.37M | 1.82M |
| Total Debt | 419K | 14K | 176K | 317K | 139K | 0 |
| Net Debt | -61.68M | -45.53M | -74.12M | -150.07M | -163.23M | -37.28M |
| Debt / Equity | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x | - |
| Debt / EBITDA | -0.00x | - | - | - | - | - |
| Net Debt / EBITDA | 0.41x | - | - | - | - | - |
| Interest Coverage | - | - | - | - | - | - |
| Total Equity | 323.98M | 307.22M | 257.65M | 151.3M | 174.46M | 41.22M |
| Equity Growth % | 73.34% | 19.24% | 70.3% | -13.28% | 323.24% | - |
| Book Value per Share | 7.19 | 7.99 | 8.19 | 4.73 | 5.21 | 32.30 |
| Total Shareholders' Equity | 323.98M | 307.22M | 257.65M | 151.3M | 174.46M | 41.22M |
| Common Stock | 5K | 4K | 3K | 0 | 0 | 0 |
| Retained Earnings | -447.96M | -404.64M | -238.33M | -157.84M | -88.51M | -51.61M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -270K | 14K | -211K | 0 | 0 | -2K |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 |
Binary clinical trial failure
As reported in recent financial filings, ArriVent's cash position has declined from a peak of $317.4 million in 2024Q1 to just $62.1 million by 2026Q1, signaling a rapid depletion of resources as the company accelerates its late-stage clinical development activities.
The consistent decline in total assets over the last two years reflects the aggressive consumption of capital to fund the FURVENT trial. This trajectory suggests that the company is approaching a critical juncture where the current balance sheet may no longer support the required R&D intensity without external intervention.
Based on the latest quarterly data, ArriVent's cash reserves of $62.1 million in 2026Q1 represent a significant reduction from prior periods, leaving the firm with a narrowing buffer to manage the high fixed costs associated with its ongoing Phase 3 clinical trial execution.
While the current ratio remains elevated at 13.95, this metric is somewhat misleading for a pre-revenue biotech where liquidity is defined by the absolute cash runway rather than working capital efficiency. Investors should monitor the burn rate closely, as the current cash balance appears insufficient to sustain operations through the completion of the primary clinical endpoints.
According to the company's balance sheet, the accumulated deficit has ballooned to $448.0 million as of 2026Q1, which significantly offsets the equity base and highlights the substantial capital investment required to advance the firm's lead asset toward potential regulatory approval.
The persistent growth in the accumulated deficit is a direct consequence of the company's pre-revenue status and the heavy R&D investment cycle. This trend suggests that shareholder equity is being systematically eroded, placing increased pressure on the success of the lead drug candidate to justify the historical capital expenditure.
Financial statements indicate that ArriVent's asset base is almost entirely composed of cash and equivalents, with negligible investment in tangible property or equipment, which may mask the underlying operational risk inherent in a firm that lacks a diversified physical infrastructure to support commercialization.
The absence of significant PPE suggests that the company is entirely reliant on third-party clinical sites and manufacturing partners, creating a potential bottleneck if external relationships are disrupted. This asset-light model, while typical for early-stage biotech, leaves the firm uniquely vulnerable to operational shocks that could delay the regulatory timeline.
Quick answers to the most common questions about buying AVBP stock.
As of 2025, ArriVent BioPharma, Inc. Common Stock (AVBP) had total assets of $333.2M including $332.9M in current assets.
ArriVent BioPharma, Inc. Common Stock (AVBP) carries total debt of $0.0M, offset by $312.8M in cash and short-term investments. Comparing total debt to cash helps evaluate the company's debt burden and net leverage.
ArriVent BioPharma, Inc. Common Stock (AVBP) has total shareholders' equity (book value) of $307.2M ($7.99 book value per share). Book value represents the net worth of the company belonging to common stock holders.
ArriVent BioPharma, Inc. Common Stock (AVBP) reported a current ratio of 12.83x. A current ratio above 1.0x indicates that the company has more current assets than current liabilities, suggesting sufficient short-term liquidity.